Clavulox Palatable Drops is for oral treatment of bacterial infections caused by susceptible organisms in cats and dogs. Clinically, Clavulox has been shown to be effective in treating a wide range of diseases of cats and dogs including: skin disease (including deep and superficial pyodermas), urinary tract infection, respiratory disease (involving upper and lower respiratory tract), and enteritis.
Resistance to many antibiotics is caused by ß-lactamase enzymes that destroy the antibiotic before it can act on the bacteria.The clavulanate in Clavulox counteracts this defence mechanism by inactivating the ß-lactamases, thus rendering the organisms sensitive to the rapid bactericidal effect of amoxycillin at concentrations readily attainable in the body. In vitro, Clavulox is active against a wide range of clinically important bacteria including: Gram+ve: Staphylococcusspp. (including ß-lactamase producing strains),Corynebacterium spp, Streptococcusspp. Gram-ve: Escherichia coli (including ß-lactamase producing strains), Salmonella spp. (including ß-lactamase producing strains), Bordetella bronchiseptica, Pasteurella, Proteus mirabilis and other sensitive strains, Klebsiella. This product is not indicated for cases involving Pseudomonas spp.
- Clavulox is a reliable broad spectrum treatment and has an excellent safety profile.
- Clavulox has been specifically designed for animal use. The novel formulation of Clavulox increases the high cure rates achieved with amoxycillin alone.
- Clavulox has activity against both gram positive and gram negative aerobes and anaerobes.
- Clavulox has proven success against mixed bacterial infections in most body tissues.
- After many years of extensive use in animals, bacterial susceptibility remains high1.
- Clavulox Palatable Drops are ideal for difficult to pill cats and small dogs. They can be given directly into the mouth or added to the food.
- Excellent absorption and penetration ensures therapeutic levels of Clavulox at infection sites enabling the achievement of clinical success. Absorption is not significantly affected by food.
Clavulox Palatable Drops are available in bottles containing an off-white powder which, when reconstituted with 14mL of water, provides 15mL of solution. Each mL of solution contains 12.5mg of clavulanic acid as potassium clavulanate and 50mg amoxycillin as amoxycillin trihydrate equivalent to 62.5mg/mL Clavulox. A dropper with 0.25 to 1.0mL graduations is included in each pack.
For oral administration only. Add 14 mL of water and shake vigorously. The standard dose is 12.5mg/kg (1 mL/5 kg) bodyweight twice daily. Refractory cases may require doubling the dose to 25mg/kg twice daily. For accurate dosing of particularly small animals, it is valuable to note that one drop from the dropper provided, contains approximately 2.5 mg Clavulox. Therefore, 5 drops/kg twice daily is recommended as a guide.
Treatment should be continued for 5–7 days or for 48 hours after all symptoms have subsided. In chronic or refractory cases, and/or where there is considerable tissue damage, a longer course may be required to allow sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:
Chronic skin disease
Store made-up suspension in a refrigerator at 2–8°C. Discard any unused suspension after 10 days.Otherwise store below 25°C (air conditioning) in a dry place.
Do not administer to small herbivores (eg. guinea pigs or rabbits) or animals with a history of allergic reactions to penicillins.
Contains amoxycillin, a semi-synthetic penicillin, and has the potential for producing hypersensitivity reactions following inhalation, ingestion or skin contact. Do not handle the product if you know you are sensitised to, or if you have been advised not to work with, such preparations.
Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. CLAVULOX is a registered trade mark of GlaxoSmithKline NZ Ltd. ACVM Registration No. A4925. RVM; Available only under Veterinary Authorisation.
- Helen Hefferman, Scientist, ESR: Surveillance of Antimicrobial Resistance Among Animal Pathogens In New Zealand, 2001.
For technical enquiries please phone Zoetis Technical Services on 0800 650 277
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.